查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1492256

CD40 配体市场：按类型、应用程式和最终用户划分 - 2024-2030 年全球预测

CD40 Ligand Market by Type (Monoclonal Antibody, Polyclonal Antibody), Application (Autoimmune Disease Treatment, Immunotherapy, Vaccine Development), End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

CD40配体市场规模预计2023年为6.9721亿美元，预计2024年将达到7.345亿美元，2030年将达到10.1229亿美元，复合年增长率为5.47%。

CD40配体（CD40L）是主要存在于T细胞上的重要分子，在免疫反应中扮演重要角色。因此，它们在免疫疾病、某些癌症和自体免疫疾病的治疗方法的开发中发挥着重要作用。在治疗应用中，基于 CD40L 的疗法对于治疗淋巴瘤和白血病等疾病至关重要，并且可能透过增强免疫系统对抗癌细胞的能力而扩展到固体癌。此外，CD40L在自体免疫疾病中的功能表明，其调节可能会降低全身性红斑性狼疮和类风湿性关节炎等疾病的严重程度。在疫苗开发中，CD40L介导的免疫反应增强有可能显着提高疫苗针对多种疾病的效力。 CD40配体市场的成长受到以下因素的推动：技术进步扩大了CD40L标靶疗法的功效和范围、相关疾病盛行率的上升、公共和私人投资支持的持续研究和开发以及新的研究和开发受到多种因素的影响，包括有利的因素促进治疗方法的核准和市场进入的监管条件。市场扩张的机会包括将 CD40L 疗法与个人基因谱相匹配的个人化医疗、加强合作以加速开发，以及进入医疗投资迅速增加的新兴市场。然而，市场面临复杂且成本高昂的监管核准流程以及高昂的製造成本等挑战，阻碍了准入。此外，CD40L 在各种疾病中的作用背后的复杂科学进一步增加了普遍有效治疗方法的开发的复杂性。这是未来研究的一个令人兴奋的领域，因为对先进药物传输系统、联合治疗和基因疗法等创新方法的投资将改善治疗结果并减少副作用。

主要市场统计
基准年[2023] 6.9721 亿美元
预测年份 [2024] 7.345 亿美元
预测年份 [2030] 1,012,290,000 美元
复合年增长率（%） 5.47%

区域洞察

美洲，特别是美国和加拿大，对慢性发炎和癌症治疗有着浓厚的兴趣。该地区的特点是强大的研究活动、大量的专利申请以及积极的法规环境，这些都刺激了对先进医疗保健解决方案的需求。同样，欧洲卓越的生物技术和製药基础设施，特别是在德国、法国和英国，以欧洲药品管理局 (EMA) 简化的核准流程为基础，并因其在自体免疫疾病和癌症治疗中的作用而得到认可。在亚太地区，中国、日本和印度正积极加强其医疗保健系统。中国正在扩大其生物製药领域，日本在医疗保健技术方面不断创新，印度正在探索具有成本效益的生物相似药治疗。所有这些努力都表明人们对 CD40 配体治疗的兴趣日益浓厚。同时，在中东和非洲（EMEA），沙乌地阿拉伯和阿拉伯联合大公国等富裕国家正在投资尖端医疗保健研究，而非洲国家则专注于基本医疗保健需求，这表现出了多样化的做法，包括逐步进行。这些地区的消费者需求和购买行为差异很大。在美洲和欧洲，消费者的意识很高，对强调药物功效和安全性的下一代治疗方法抱有很高的期望。亚太地区的消费者越来越注重健康，寻求先进的治疗方法，但也注重成本。另一方面，在非洲，中东的富人对更先进的治疗方法有着浓厚的兴趣，但减轻医疗费用负担仍然是首要关注的问题。

FPNV定位矩阵

FPNV定位矩阵对于评估CD40配体市场供应商的市场定位至关重要。此矩阵提供了对供应商的全面评估，并检查了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对 CD40 配体市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该行业竞争力的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对 CD40 配体市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 自体免疫疾病和癌症的发生率上升
      • 生物技术和分子生物学的进展
      • 医疗保健支出和研发投资增加
    • 抑制因素
      • 监管要求严格，产品开发高成本
    • 机会
      • 增加对免疫肿瘤学的投资
      • 生物技术和製药巨头之间合作的机会，以加速创新治疗方法的开发和分销
    • 任务
      • CD40配体的复杂机制
  • 市场区隔分析
    • 类型：针对多种应用的基于 CD40 配体的多株抗体的广泛研究
    • 应用：CD40配体在免疫学和肿瘤学领域医学进展的应用
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 CD40 配体市场：依类型

  • 单株抗体
  • 多株抗体

第七章 CD40 配体市场：依应用分类

  • 自体免疫疾病的治疗
  • 免疫疗法
  • 疫苗开发

第 8 章 CD40 配体市场：依最终用户分类

  • 医疗服务提供方
  • 製药公司
  • 调查机构

第9章美洲CD40配体市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区CD40配体市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲CD40配体市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Kiniksa Pharmaceuticals 推动干燥症新阶段的免疫调节疗法和类风湿性关节炎的最新研究成果
    • 异种移植的突破：Eledon Pharmaceuticals 的 tegopulvert 对于历史性的猪对人类心臟移植至关重要
    • 赛诺菲将多发性硬化症治疗药物 Flexaliumab 推进第 3 期试验
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-5D693B46BCF8

[192 Pages Report] The CD40 Ligand Market size was estimated at USD 697.21 million in 2023 and expected to reach USD 734.50 million in 2024, at a CAGR 5.47% to reach USD 1,012.29 million by 2030.

The CD40 Ligand (CD40L) is a critical molecule found predominantly on T cells, playing a vital role in immune responses. This makes it intensely relevant in developing treatments for immune disorders, specific cancers, and autoimmune diseases. In therapeutic applications, CD40L-based treatments are crucial for managing conditions such as lymphoma and leukemia, potentially extending to some solid tumors by boosting the immune system's ability to fight cancer cells. Furthermore, CD40L's function in autoimmune disorders suggests its modulation could lessen disease severity in ailments such as systemic lupus erythematosus and rheumatoid arthritis. In vaccine development, enhancing immune responses through CD40L could significantly improve vaccine efficacy against various diseases. CD40 Ligand market growth is influenced by several factors including technological advancements that increase the efficacy and scope of CD40L-targeted therapies, the rising prevalence of related diseases, ongoing research and development supported by public and private investments, and favorable regulatory conditions which expedite the approval and market entry of novel treatments. Opportunities for market expansion include personalizing medicine to tailor CD40L therapies to individual genetic profiles, fostering collaborations that speed development, and penetrating emerging markets where healthcare investments are escalating. However, the market faces challenges such as complex and costly regulatory approval processes and high production costs which hinder accessibility. Moreover, the intricate science behind CD40L's role across various diseases adds another layer of complexity to developing universally effective therapies. Investment in innovative approaches such as advanced drug delivery systems, combination therapies, and gene therapy enhance treatment outcomes and reduce side effects, making these promising areas for future research.

KEY MARKET STATISTICS
Base Year [2023] USD 697.21 million
Estimated Year [2024] USD 734.50 million
Forecast Year [2030] USD 1,012.29 million
CAGR (%) 5.47%

Regional Insights

In the Americas, particularly the United States and Canada, there is a strong focus on chronic inflammation and cancer therapies. The region is characterized by intense research activities, numerous patent filings, and a vigorous regulatory environment that fuels the demand for advanced healthcare solutions. Similarly, Europe's notable biotech and pharmaceutical infrastructure, especially in Germany, France, and the UK, fosters significant advancements in autoimmune and cancer treatments, supported by streamlined approval processes by the European Medical Agency (EMA). In the Asia Pacific, China, Japan, and India are aggressively pursuing enhancements in their healthcare systems. China is expanding its biopharmaceutical sector, Japan continues to innovate in healthcare technology, and India is pushing forward with research in cost-effective biosimilar treatments. All these efforts point to a growing interest in therapies that involve CD40 ligand. Meanwhile, the Middle East and Africa (EMEA) display a diverse approach; wealthier nations including Saudi Arabia and the UAE invest in cutting-edge healthcare research, whereas African countries focus more on foundational healthcare needs while gradually stepping into complex cancer treatment research. Consumer needs and purchasing behavior vary significantly across these regions. In the Americas and Europe, there is a high consumer awareness and an expectation for next-generation treatments, with a strong emphasis on drug efficacy and safety. Asia Pacific consumers are increasingly health-conscious, seeking advanced treatments but are sensitive to cost. In contrast, the primary concern in much of Africa remains essential healthcare affordability, though there is a keen interest in more sophisticated treatments among wealthier segments in the Middle East.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the CD40 Ligand Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising prevalence of autoimmune diseases and cancers
      • Advancements in biotechnology and molecular biology
      • Increased healthcare spending and R&D investments
    • Market Restraints
      • Stringent regulatory requirements and high cost of product development
    • Market Opportunities
      • Growing Investment in Immuno-Oncology
      • Opportunities for partnerships between biotech firms and pharmaceutical giants to accelerate innovative therapies development and distribution
    • Market Challenges
      • Complex mechanisms of the CD40 ligand
  • Market Segmentation Analysis
    • Type: Extensive research in CD40 Ligand based polyclonal antibodies for diverse applications
    • Application: Applications of CD40 Ligand in advancing medical treatments in field of immunology and oncology
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the CD40 Ligand Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the CD40 Ligand Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Kiniksa Pharmaceuticals Advances Immune-Modulating Therapies with a New Phase in Sjogren's Disease and Updated Rheumatoid Arthritis Study Results

Kiniksa Pharmaceuticals, Ltd., a player in developing treatments for autoimmune and cardiovascular diseases, has announced the beginning of a Phase 2b trial of their drug, abiprubart, in patients with Sjogren's Disease. In addition, the company revealed findings from the fourth cohort of a Phase 2 clinical trial for the same drug in treating rheumatoid arthritis. Abiprubart, which is still under investigation, is a humanized antibody aimed at disrupting the interaction between CD40 and CD40 ligand (CD154), a mechanism believed to regulate immune responses involved in these conditions. [Published On: 2024-04-02]

Breakthrough in Xenotransplantation: Eledon Pharmaceuticals' Tegoprubart Integral to Historic Pig-to-Human Heart Transplant

Eledon Pharmaceuticals, Inc. reported that its experimental treatment, tegoprubart, the company's investigational anti-CD40 antibody, played a key role in the immunosuppressive therapy used during a pioneering pig-to-human heart transplant. The procedure, the second of its kind, was conducted on September 20th at the University of Maryland Medical Center and involved a 58-year-old male patient with heart failure. The utilization of tegoprubart, an anti-CD40 antibody, marks a significant advancement in transplant medicine and genetic engineering. [Published On: 2023-09-24]

Sanofi Advances Promising Multiple Sclerosis Treatment, Frexalimab, into Phase 3 Trials

Sanofi is set to progress its novel drug candidate, frexalimab, into phase 3 trials following successful mid-stage results for the treatment of multiple sclerosis. In clinical studies, the higher dosage of frexalimab led to a significant 89% decline in the formation of gadolinium-enhancing T1 brain lesions, which are indicative of active disease inflammation, after 12 weeks. Furthermore, at the 24-week mark, a remarkable 96% of patients receiving this dose exhibited no new T1 lesions, highlighting the potential effectiveness of frexalimab in controlling disease progression. [Published On: 2023-06-01]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the CD40 Ligand Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the CD40 Ligand Market, highlighting leading vendors and their innovative profiles. These include Abcam Limited by Danaher Corporation, ACROBiosystems, Bio-Techne Corporation, BioLegend, Inc. by PerkinElmer, Inc., BPS Bioscience, Inc., Cell Signaling Technology, Inc., Creative Biolabs, Cytek Biosciences, Inc., Eledon Pharmaceuticals, Inc., Enzo Life Sciences, Inc.,, FUJIFILM Irvine Scientific., Gemini BioProducts LLC, Kiniksa Pharmaceuticals, Ltd., Leinco Technologies, Inc., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Sino Biological, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the CD40 Ligand Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Monoclonal Antibody
    • Polyclonal Antibody
  • Application
    • Autoimmune Disease Treatment
    • Immunotherapy
    • Vaccine Development
  • End-Users
    • Healthcare Providers
    • Pharmaceutical Companies
    • Research Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of autoimmune diseases and cancers
      • 5.1.1.2. Advancements in biotechnology and molecular biology
      • 5.1.1.3. Increased healthcare spending and R&D investments
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory requirements and high cost of product development
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing Investment in Immuno-Oncology
      • 5.1.3.2. Opportunities for partnerships between biotech firms and pharmaceutical giants to accelerate innovative therapies development and distribution
    • 5.1.4. Challenges
      • 5.1.4.1. Complex mechanisms of the CD40 ligand
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Extensive research in CD40 Ligand based polyclonal antibodies for diverse applications
    • 5.2.2. Application: Applications of CD40 Ligand in advancing medical treatments in field of immunology and oncology
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. CD40 Ligand Market, by Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibody
  • 6.3. Polyclonal Antibody

7. CD40 Ligand Market, by Application

  • 7.1. Introduction
  • 7.2. Autoimmune Disease Treatment
  • 7.3. Immunotherapy
  • 7.4. Vaccine Development

8. CD40 Ligand Market, by End-Users

  • 8.1. Introduction
  • 8.2. Healthcare Providers
  • 8.3. Pharmaceutical Companies
  • 8.4. Research Institutions

9. Americas CD40 Ligand Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific CD40 Ligand Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa CD40 Ligand Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Kiniksa Pharmaceuticals Advances Immune-Modulating Therapies with a New Phase in Sjogren's Disease and Updated Rheumatoid Arthritis Study Results
    • 12.3.2. Breakthrough in Xenotransplantation: Eledon Pharmaceuticals' Tegoprubart Integral to Historic Pig-to-Human Heart Transplant
    • 12.3.3. Sanofi Advances Promising Multiple Sclerosis Treatment, Frexalimab, into Phase 3 Trials
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CD40 LIGAND MARKET RESEARCH PROCESS
  • FIGURE 2. CD40 LIGAND MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CD40 LIGAND MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CD40 LIGAND MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CD40 LIGAND MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CD40 LIGAND MARKET DYNAMICS
  • FIGURE 7. GLOBAL CD40 LIGAND MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CD40 LIGAND MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CD40 LIGAND MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CD40 LIGAND MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CD40 LIGAND MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES CD40 LIGAND MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. CD40 LIGAND MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. CD40 LIGAND MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CD40 LIGAND MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CD40 LIGAND MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CD40 LIGAND MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CD40 LIGAND MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CD40 LIGAND MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CD40 LIGAND MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CD40 LIGAND MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CD40 LIGAND MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CD40 LIGAND MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CD40 LIGAND MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CD40 LIGAND MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CD40 LIGAND MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CD40 LIGAND MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CD40 LIGAND MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CD40 LIGAND MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CD40 LIGAND MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CD40 LIGAND MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS CD40 LIGAND MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES CD40 LIGAND MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES CD40 LIGAND MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 283. CD40 LIGAND MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. CD40 LIGAND MARKET, FPNV POSITIONING MATRIX, 2023